C
VNDA icon

Covestor’s Vanda Pharmaceuticals VNDA Stock Holding History

Covestor’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-66
Closed – – 2780
2025
Q3 		$0 Buy
66
+37
+128% +$171 ﹤0.01% 2820
2025
Q2 		$0 Buy
+29
New +$127 ﹤0.01% 2799
2024
Q2 		– Sell
-286
Closed -$1K – 2802
2024
Q1 		$1K Sell
286
-23
-7% -$92 ﹤0.01% 2137
2023
Q4 		$1K Buy
309
+97
+46% +$391 ﹤0.01% 2050
2023
Q3 		$1K Buy
212
+38
+22% +$211 ﹤0.01% 2016
2023
Q2 		$1K Sell
174
-367
-68% -$2.35K ﹤0.01% 2032
2023
Q1 		$4K Buy
541
+275
+103% +$1.93K ﹤0.01% 1636
2022
Q4 		$2K Sell
266
-13
-5% -$127 ﹤0.01% 1816
2022
Q3 		$3K Sell
279
-7
-2% -$74 ﹤0.01% 1657
2022
Q2 		$3K Sell
286
-14
-5% -$145 ﹤0.01% 1568
2022
Q1 		$3K Buy
300
+224
+295% +$2.94K ﹤0.01% 1632
2021
Q4 		$1K Buy
+76
New +$1.32K ﹤0.01% 1979

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Covestor's VNDA Position: Q4 2025 in Review

Covestor sold out of Vanda Pharmaceuticals (VNDA) in Q4 2025, closing a stake of 66 shares.

Covestor first reported a position in VNDA in Q4 2021 and held it in 12 quarters. The position peaked at $4K in Q1 2023. 153 funds tracked by Wall St. Rank hold VNDA as of Q4 2025.

  • Covestor reported no remaining Vanda Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Covestor sold 66 Vanda Pharmaceuticals shares in Q4 2025.
  • Covestor first reported a position in Vanda Pharmaceuticals in Q4 2021 and held it in 12 quarters.
  • Covestor's Vanda Pharmaceuticals position peaked at $4K in Q1 2023.
  • 153 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2025.

Based on Covestor's 13F filing for Q4 2025, filed 6 Feb 2026.